Last reviewed · How we verify
LY3041658
At a glance
| Generic name | LY3041658 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (PHASE2)
- A Study of LY3041658 in Adults With Hidradenitis Suppurativa (PHASE2)
- A Study of LY3041658 in Healthy Participants (PHASE1)
- A Study of LY3041658 in Participants With Skin Diseases (PHASE1)
- Safety Study of LY3041658 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3041658 CI brief — competitive landscape report
- LY3041658 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI